NATCO Pharma Ltd.
NATCOPHARMHealthcare filings
We hold this company’s filings and have not read the financial statements out of them yet. Every filing on record is listed under filings, and each one opens.
Earnings calls
21 transcript(s)/analyst meet(s) served; 17 document(s) on file are not transcripts (cover letters, duplicates, unresolved) and are excluded. Speaker attribution is shown only where the segmenter attributes ≥ 95% of sentences to management or analysts (0 of 21 documents here); elsewhere sentences render unattributed.
| Kind | Date | Period | Served | Attribution rate |
|---|---|---|---|---|
| TRANSCRIPT | 20220817 | 2021-06-30 | yes | |
| COVER_LETTER | 20220531 | 2022-03-31 | no | |
| TRANSCRIPT | 20220604 | 2022-03-31 | yes | |
| COVER_LETTER | 20220810 | 2022-06-30 | no | |
| COVER_LETTER | 20221111 | 2022-09-30 | no | |
| COVER_LETTER | 20230210 | 2022-12-31 | no | |
| TRANSCRIPT | 20230213 | 2022-12-31 | yes | |
| COVER_LETTER | 20230530 | 2023-03-31 | no | |
| TRANSCRIPT | 20230601 | 2023-03-31 | yes | |
| COVER_LETTER | 20230810 | 2023-06-30 | no | |
| TRANSCRIPT | 20230814 | 2023-06-30 | yes | |
| TRANSCRIPT | 20240221 | 2023-12-31 | yes | |
| TRANSCRIPT | 20240604 | 2024-03-31 | yes | |
| TRANSCRIPT | 20250604 | 2024-03-31 | yes | |
| TRANSCRIPT | 20240813 | 2024-06-30 | yes | |
| COVER_LETTER | 20240813 | 2024-06-30 | no | |
| DUPLICATE | 20240813 | 2024-06-30 | no | |
| DUPLICATE | 20240821 | 2024-06-30 | no | |
| DUPLICATE | 20240821 | 2024-06-30 | no | |
| TRANSCRIPT | 20250819 | 2024-06-30 | yes | |
| TRANSCRIPT | 20241121 | 2024-09-30 | yes | |
| TRANSCRIPT | 20251115 | 2024-09-30 | yes | |
| COVER_LETTER | 20251115 | 2024-09-30 | no | |
| TRANSCRIPT | 20250219 | 2024-12-31 | yes | |
| ANALYST_MEET | 20250724 | 2025-06-30 | yes | |
| COVER_LETTER | 20250724 | 2025-06-30 | no | |
| DUPLICATE | 20250729 | 2025-06-30 | no | |
| COVER_LETTER | 20260814 | 2025-06-30 | no | |
| DUPLICATE | 20260818 | 2025-06-30 | no | |
| DUPLICATE | 20251120 | 2025-09-30 | no | |
| TRANSCRIPT | 20260604 | 2026-03-31 | yes | |
| DUPLICATE | 20260604 | 2026-03-31 | no | |
| TRANSCRIPT | 20260814 | 2026-06-30 | yes |
NATCOPHARM
files the standard Schedule III statements. Every figure below opens to the filing it was read from; where a figure is not shown, the reason is printed in its place.
Identity
| Statement division | general |
| Scope served | consolidated |
| Panels on this page | 4 |
Market
No split, bonus or consolidation is on record for this company inside the period this price series covers, so the closes need no adjustment.
| Last close | 842.00 |
| 52-week range | 792.95 – 1206.0 |
| Return 1M | -2.8% |
| Return 3M | -6.83% |
| Return 1Y | -1.43% |
| Return 3Y | -0.77% |
| Return 5Y | -4.31% |
| Market capitalisation | not shown — we could not confirm it |
| Shares outstanding | not shown — we could not confirm it |
| P/E | not shown — we could not confirm it |
| P/B | not shown — we could not confirm it |
| EV/EBITDA | not shown — we could not confirm it |
Latest quarter filed — period ending 2026-06-30
In INR crore except per-share figures. `period_id` is the period the filing names for the number; the date beside each cell is when it was filed.
| Revenue from operations | 735.00 |
| Other income | 59.00 |
| Total income | 794.00 |
| Cost of materials consumed | 158.00 |
| Purchases of stock-in-trade | 28.00 |
| Changes in inventories | -38.00 |
| Employee benefit expense | 179.00 |
| Finance costs | 13.00 |
Ownership — 2026-06-30, and the change from 2026-03-31
| Holder | Per cent | Change |
|---|---|---|
| promoter and promoter group | 0.49 | 0.00 |
| institutions foreign | 0.17 | -0.00 |
| institutions domestic | 0.06 | 0.00 |
| mutual funds | 0.02 | 0.00 |
| public | 0.51 | 0.00 |
Documents on file
| Class | Most recent | On file |
|---|---|---|
| ANALYST_MEET | 2025-06-30 | 1 |
| COVER_LETTER | 2025-06-30 | 10 |
| DUPLICATE | 2026-03-31 | 7 |
| TRANSCRIPT | 2026-06-30 | 15 |
Financial statements
Filed results, consolidated, in INR crore except per-share figures. Every figure opens to the filing it was read from. Quarterly and annual columns are the periods the filing itself names, never a document date.
Quarterly results, as filed
| Line | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | 2024-09-30 | 2024-12-31 | 2025-03-31 | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 432.00 | 492.00 | 898.00 | 1,140.00 | 1,031.00 | 759.00 | 1,068.00 | 1,363.00 | 1,371.00 | 475.00 | 1,221.00 | 1,329.00 | 1,363.00 | 647.00 | 739.00 | 735.00 |
| Other income | 20.00 | 21.00 | 29.00 | 20.00 | 29.00 | 37.00 | 42.00 | 48.00 | 64.00 | 176.00 | 66.00 | 62.00 | 100.00 | 58.00 | 78.00 | 59.00 |
| Total income | 453.00 | 513.00 | 927.00 | 1,160.00 | 1,061.00 | 796.00 | 1,110.00 | 1,411.00 | 1,435.00 | 651.00 | 1,287.00 | 1,391.00 | 1,463.00 | 705.00 | 817.00 | 794.00 |
| Cost of materials consumed | 101.00 | 133.00 | 146.00 | 136.00 | 166.00 | 92.00 | 128.00 | 151.00 | 143.00 | 73.00 | 169.00 | 181.00 | 175.00 | 135.00 | 103.00 | 158.00 |
| Purchases of stock-in-trade | 47.00 | 47.00 | 51.00 | 43.00 | 41.00 | 37.00 | 31.00 | 32.00 | 54.00 | 39.00 | 41.00 | 37.00 | 73.00 | 56.00 | 38.00 | 28.00 |
| Changes in inventories | -42.00 | -64.00 | 61.00 | 17.00 | 8.00 | 33.00 | -16.00 | -4.00 | -19.00 | -29.00 | 39.00 | 15.00 | -78.00 | -58.00 | 14.00 | -38.00 |
| Employee benefit expense | 110.00 | 106.00 | 119.00 | 138.00 | 122.00 | 122.00 | 142.00 | 142.00 | 152.00 | 142.00 | 159.00 | 169.00 | 200.00 | 159.00 | 158.00 | 179.00 |
| Finance costs | 4.00 | 4.00 | 3.00 | 4.00 | 4.00 | 5.00 | 6.00 | 5.00 | 4.00 | 4.00 | 10.00 | 3.00 | 13.00 | 10.00 | 11.00 | 13.00 |
| Depreciation and amortisation | 42.00 | 42.00 | 41.00 | 44.00 | 44.00 | 44.00 | 56.00 | 44.00 | 46.00 | 47.00 | 98.00 | 58.00 | 52.00 | 46.00 | 50.00 | 47.00 |
| Other expenses | 121.00 | 166.00 | 182.00 | 278.00 | 235.00 | 206.00 | 286.00 | 236.00 | 238.00 | 212.00 | 264.00 | 356.00 | 414.00 | 196.00 | 298.00 | 222.00 |
| Total expenses | 382.00 | 432.00 | 602.00 | 660.00 | 621.00 | 539.00 | 633.00 | 607.00 | 617.00 | 487.00 | 781.00 | 819.00 | 849.00 | 544.00 | 673.00 | 609.00 |
| Profit before exceptional items and tax | 70.00 | 81.00 | 324.00 | 500.00 | 440.00 | 256.00 | 478.00 | 804.00 | 818.00 | 164.00 | 506.00 | 572.00 | 614.00 | 161.00 | 144.00 | 186.00 |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 70.00 | 81.00 | 324.00 | 500.00 | 440.00 | 256.00 | 478.00 | 804.00 | 818.00 | 164.00 | 506.00 | 572.00 | 614.00 | 161.00 | 144.00 | 186.00 |
| Current tax | 14.00 | 18.00 | 58.00 | 92.00 | 82.00 | 52.00 | 90.00 | 144.00 | 154.00 | 34.00 | 106.00 | 116.00 | 140.00 | 31.00 | 16.00 | 49.00 |
| Deferred tax | -1.00 | 1.00 | -10.00 | -12.00 | -11.00 | -9.00 | 1.00 | -8.00 | -12.00 | -2.00 | -6.00 | -24.00 | -45.00 | -11.00 | -105.00 | 15.00 |
| Tax expense | 14.00 | 19.00 | 49.00 | 80.00 | 71.00 | 44.00 | 91.00 | 135.00 | 142.00 | 31.00 | 100.00 | 92.00 | 96.00 | 21.00 | -89.00 | 63.00 |
| Profit for the period | 57.00 | 62.00 | 276.00 | 420.00 | 369.00 | 213.00 | 386.00 | 668.00 | 676.00 | 132.00 | 406.00 | 480.00 | 518.00 | 151.00 | 269.00 | 206.00 |
| Profit attributable to owners | 57.00 | 62.00 | 276.00 | 420.00 | 369.00 | 213.00 | 386.00 | 668.00 | 677.00 | 133.00 | 407.00 | 481.00 | 518.00 | 152.00 | 268.00 | 206.00 |
| Profit attributable to non-controlling interests | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -1.00 | -1.00 | -1.00 | -0.00 | -0.00 | -0.00 | 1.00 | 0.00 |
| Other comprehensive income | -4.00 | 8.00 | -0.00 | 14.00 | -5.00 | 18.00 | -12.00 | -14.00 | 19.00 | -11.00 | -18.00 | 39.00 | 40.00 | 124.00 | 83.00 | 111.00 |
| Total comprehensive income | 53.00 | 71.00 | 276.00 | 435.00 | 364.00 | 231.00 | 374.00 | 654.00 | 696.00 | 122.00 | 388.00 | 520.00 | 558.00 | 276.00 | 352.00 | 318.00 |
| Earnings per share, basic | 3.11 | 3.41 | 15.11 | 23.26 | 20.60 | 11.88 | 21.56 | 37.32 | 37.81 | 7.43 | 22.70 | 26.84 | 28.94 | 8.46 | 14.96 | 11.53 |
| Earnings per share, diluted | 3.11 | 3.41 | 15.11 | 23.26 | 20.60 | 11.88 | 21.56 | 37.32 | 37.81 | 7.43 | 22.70 | 26.84 | 28.94 | 8.46 | 14.96 | 11.53 |
Annual results, as filed
| Line | 2019-03-31 | 2020-03-31 | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2026-03-31 |
|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 2,094.00 | 1,915.00 | 2,052.00 | 1,945.00 | 2,707.00 | 3,999.00 | 4,430.00 | 4,078.00 |
| Other income | 130.00 | 107.00 | 104.00 | 99.00 | 105.00 | 128.00 | 354.00 | 298.00 |
| Total income | 2,225.00 | 2,022.00 | 2,156.00 | 2,044.00 | 2,812.00 | 4,127.00 | 4,784.00 | 4,376.00 |
| Cost of materials consumed | 333.00 | 329.00 | 373.00 | 519.00 | 475.00 | 522.00 | 536.00 | 594.00 |
| Purchases of stock-in-trade | 55.00 | 128.00 | 187.00 | 58.00 | 176.00 | 151.00 | 166.00 | 203.00 |
| Changes in inventories | -34.00 | -75.00 | -48.00 | -17.00 | -24.00 | 43.00 | -12.00 | -106.00 |
| Employee benefit expense | 356.00 | 375.00 | 415.00 | 445.00 | 487.00 | 525.00 | 594.00 | 687.00 |
| Finance costs | 19.00 | 22.00 | 13.00 | 18.00 | 14.00 | 19.00 | 24.00 | 37.00 |
| Depreciation and amortisation | 81.00 | 100.00 | 117.00 | 143.00 | 164.00 | 187.00 | 235.00 | 207.00 |
| Other expenses | 590.00 | 576.00 | 520.00 | 676.00 | 658.00 | 1,006.00 | 949.00 | 1,264.00 |
| Total expenses | 1,400.00 | 1,454.00 | 1,576.00 | 1,842.00 | 1,950.00 | 2,453.00 | 2,493.00 | 2,885.00 |
| Profit before exceptional items and tax | 825.00 | 569.00 | 580.00 | 202.00 | 862.00 | 1,674.00 | 2,291.00 | 1,491.00 |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 825.00 | 569.00 | 580.00 | 202.00 | 862.00 | 1,674.00 | 2,291.00 | 1,491.00 |
| Current tax | 188.00 | 131.00 | 141.00 | 48.00 | 163.00 | 316.00 | 438.00 | 304.00 |
| Deferred tax | -6.00 | -20.00 | -4.00 | -16.00 | -16.00 | -31.00 | -30.00 | -185.00 |
| Tax expense | 182.00 | 111.00 | 137.00 | 32.00 | 147.00 | 285.00 | 408.00 | 119.00 |
| Profit for the period | 642.00 | 458.00 | 442.00 | 170.00 | 715.00 | 1,388.00 | 1,883.00 | 1,418.00 |
| Profit attributable to owners | 644.00 | 461.00 | 441.00 | 170.00 | 715.00 | 1,388.00 | 1,885.00 | 1,418.00 |
| Profit attributable to non-controlling interests | -2.00 | -3.00 | 2.00 | 0.00 | 0.00 | 0.00 | -2.00 | 0.00 |
| Other comprehensive income | -8.00 | -14.00 | 9.00 | 50.00 | 3.00 | 15.00 | -24.00 | 287.00 |
| Total comprehensive income | 635.00 | 444.00 | 451.00 | 220.00 | 718.00 | 1,403.00 | 1,859.00 | 1,706.00 |
| Earnings per share, basic | 34.98 | 25.33 | 24.20 | 9.32 | 39.18 | 77.34 | 105.26 | 79.20 |
| Earnings per share, diluted | 34.87 | 25.26 | 24.16 | 9.32 | 39.18 | 77.34 | 105.26 | 79.20 |
Balance sheet, as filed
| Line | 2022-09-30 | 2023-03-31 | 2023-09-30 | 2024-03-31 | 2024-09-30 | 2025-03-31 | 2025-09-30 | 2026-03-31 |
|---|---|---|---|---|---|---|---|---|
| Total assets | 5,078.00 | 5,657.00 | 6,254.00 | 6,906.00 | 8,245.00 | 8,631.00 | 10,430.00 | 11,074.00 |
| Non-current assets | 2,675.00 | 2,657.00 | 2,904.00 | 2,883.00 | 3,243.00 | 3,361.00 | 3,463.00 | 6,021.00 |
| Current assets | 2,403.00 | 3,000.00 | 3,350.00 | 4,024.00 | 5,002.00 | 5,270.00 | 6,967.00 | 5,052.00 |
| Property, plant and equipment | 2,188.00 | 2,239.00 | 2,270.00 | 2,298.00 | 2,304.00 | 2,432.00 | 2,437.00 | 2,545.00 |
| Capital work-in-progress | 144.00 | 64.00 | 84.00 | 137.00 | 234.00 | 225.00 | 255.00 | 294.00 |
| Goodwill | 51.00 | 55.00 | 56.00 | 56.00 | 56.00 | 57.00 | 60.00 | 63.00 |
| Other intangible assets | 140.00 | 133.00 | 143.00 | 137.00 | 181.00 | 209.00 | 200.00 | 194.00 |
| Inventories | 749.00 | 743.00 | 710.00 | 700.00 | 775.00 | 766.00 | 818.00 | 908.00 |
| Trade receivables | 371.00 | 856.00 | 1,120.00 | 1,189.00 | 1,436.00 | 1,247.00 | 1,719.00 | 881.00 |
| Cash and cash equivalents | 108.00 | 132.00 | 104.00 | 70.00 | 105.00 | 120.00 | 104.00 | 199.00 |
| Total equity and liabilities | 5,078.00 | 5,657.00 | 6,254.00 | 6,906.00 | 8,245.00 | 8,631.00 | 10,430.00 | 11,074.00 |
| Equity | 4,571.00 | 4,874.00 | 5,294.00 | 5,853.00 | 7,157.00 | 7,612.00 | 8,654.00 | 9,221.00 |
| Equity share capital | 36.00 | 36.00 | 36.00 | 36.00 | 36.00 | 36.00 | 36.00 | 36.00 |
| Other equity | 4,535.00 | 4,837.00 | 5,258.00 | 5,817.00 | 7,114.00 | 7,571.00 | 8,614.00 | 9,185.00 |
| Total liabilities | 507.00 | 784.00 | 960.00 | 1,053.00 | 1,088.00 | 1,018.00 | 1,776.00 | 1,853.00 |
| Non-current liabilities | 106.00 | 100.00 | 82.00 | 80.00 | 79.00 | 75.00 | 76.00 | 172.00 |
| Current liabilities | 401.00 | 683.00 | 878.00 | 973.00 | 1,009.00 | 944.00 | 1,700.00 | 1,681.00 |
| Borrowings, non-current | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 100.00 |
| Borrowings, current | 83.00 | 165.00 | 239.00 | 363.00 | 201.00 | 273.00 | 253.00 | 606.00 |
| Trade payables | 143.00 | 264.00 | 366.00 | 236.00 | 314.00 | 275.00 | 513.00 | 409.00 |
Cash flow, as filed
| Line | 2022-09-30 | 2023-03-31 | 2023-09-30 | 2024-03-31 | 2024-09-30 | 2025-03-31 | 2025-09-30 | 2026-03-31 |
|---|---|---|---|---|---|---|---|---|
| Net cash from operating activities | 734.00 | 849.00 | 632.00 | 1,212.00 | 1,137.00 | 1,697.00 | 1,191.00 | 1,768.00 |
| Net cash from investing activities | -347.00 | -477.00 | -348.00 | -1,033.00 | -882.00 | -1,414.00 | -1,189.00 | -2,143.00 |
| Net cash from financing activities | -395.00 | -363.00 | -314.00 | -247.00 | -219.00 | -211.00 | -76.00 | 298.00 |
| Purchase of property, plant and equipment | 96.00 | 146.00 | 148.00 | 339.00 | 169.00 | 401.00 | 180.00 | 388.00 |
| Net increase in cash | -3.00 | 21.00 | -28.00 | -62.00 | 34.00 | 50.00 | -16.00 | 79.00 |
| con:CFO.BEFORE_TAX | 819.00 | 1,027.00 | 749.00 | 1,498.00 | 1,322.00 | 2,069.00 | 1,390.00 | 2,166.00 |
| con:INTEREST_RECEIVED.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:INTEREST_PAID.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:DIVIDENDS_RECEIVED.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:TAX_PAID.OPERATING | 85.00 | 178.00 | 117.00 | 286.00 | 186.00 | 373.00 | 200.00 | 398.00 |
| con:CF_OTHER.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:INVESTMENTS_PURCHASED | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:INVESTMENTS_SOLD | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:PPE_DISPOSALS | 20.00 | 30.00 | 5.00 | 2.00 | 50.00 | 95.00 | 2.00 | 1.00 |
| con:CF_INVESTING.SUBSIDIARIES_SOLD | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.SUBSIDIARIES_ACQUIRED | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.JV_SOLD | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.JV_ACQUIRED | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2,140.00 |
Who owns it
The shareholding pattern filed with the exchange every quarter, as a series. Percentages are of total shares. Each figure names the filing it was read from and the date it was filed.
| Holder | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | 2024-09-30 | 2024-12-31 | 2025-03-31 | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter and promoter group | 48.84 | 49.76 | 49.71 | 49.71 | 49.71 | 49.71 | 49.62 | 49.62 | 49.56 | 49.56 | 0.49 | 0.49 | 0.49 | 0.49 |
| Domestic institutions | 15.38 | 15.15 | 14.01 | 11.25 | 9.70 | 7.87 | 6.75 | 5.57 | 5.65 | 5.82 | 0.06 | 0.05 | 0.05 | 0.06 |
| Mutual funds | — | — | — | — | — | — | — | — | — | 2.11 | 0.02 | 0.02 | 0.02 | 0.02 |
| Insurance companies | 6.42 | 5.57 | 6.34 | 6.04 | 5.58 | 5.09 | 4.23 | 3.33 | 3.39 | 3.43 | 0.03 | 0.04 | 0.03 | 0.04 |
| Foreign institutions | 11.91 | 11.02 | 12.82 | 13.72 | 16.14 | 17.45 | 17.51 | 17.94 | 17.49 | 15.51 | 0.14 | 0.15 | 0.17 | 0.17 |
| Government | — | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Public | 51.16 | 50.24 | 50.29 | 50.29 | 50.29 | 50.29 | 50.38 | 50.38 | 50.44 | 50.44 | 0.51 | 0.51 | 0.51 | 0.51 |
| Non-institutional | 23.87 | 24.07 | 23.46 | 25.32 | 24.45 | 24.97 | 26.12 | 26.87 | 27.29 | 29.11 | 0.31 | 0.30 | 0.28 | 0.28 |
| Shares outstanding | 182470115 | 179109870 | 179109870 | 179109870 | 179109870 | 179109870 | 179109870 | 179109870 | 179109870 | 179109870 | 179109870 | 179109870 | 179109870 | 179109870 |
Related parties
Transactions with related parties as disclosed to the exchange for the period ending 2024-09-30, by counterparty, largest first. Amounts are as filed. Each row names the filing and the date it was filed.
| Counterparty | Relationship | Type | Amount in the period | Transactions |
|---|---|---|---|---|
| Natco Pharma (Canada) Inc. Canada | Subsidiary Company | Sale of goods or services | 378,000,000.00 | 1 |
| Natcofarma Do Brasil Ltda., Brazil | Step down Subsidary | Sale of goods or services | 236,030,000.00 | 1 |
| PT NATCO Lotus Farma | Subsidiary Company | Investment, Sale of goods or services | 80,830,000.00 | 2 |
| Natco Pharma Asia Pte Ltd, Singapore | Subsidiary Company | Sale of goods or services | 67,190,000.00 | 1 |
| Natco Trust | Entities in which Directors have c | Any other transaction | 62,730,000.00 | 2 |
| NATCO Pharma USA LLC, United States of America | Step down Subsidary | Sale of goods or services | 47,200,000.00 | 1 |
| Natco Lifesciences Philippines Inc., Philippines | Subsidiary Company | Interest received, Loan, Sale of goods or services | 16,790,000.00 | 3 |
| V C Nannapaneni | Key Managerial Personnel | Any other transaction, Remuneration | 11,400,000.00 | 3 |
| Rajeev Nannapaneni | Key Managerial Personnel | Any other transaction, Remuneration | 10,650,000.00 | 3 |
| Dr. Pavan Bhat Ganapati | Key Managerial Personnel | Remuneration | 8,430,000.00 | 1 |
| Potluri Prasad Sivaramakrishna | Key Managerial Personnel | Remuneration | 7,900,000.00 | 1 |
| Dr.Lingarao Donthineni | Key Managerial Personnel | Remuneration | 7,900,000.00 | 1 |
| S V V N Appa Rao | Chief Financial Officer | Remuneration | 4,480,000.00 | 1 |
| Time Cap Pharma Labs Private Limited | Entities in which Directors have c | Any other transaction | 3,630,000.00 | 1 |
| Venkat Ramesh Chekuri | Company Secretary | Remuneration | 1,010,000.00 | 1 |
What management said
Every earnings call we hold for this company, read in full. Prepared remarks are separated from the question-and-answer session and every paragraph names who said it and on which page. These are management’s own words, not filed figures.
| Date | Quarter | Who spoke | |
|---|---|---|---|
| 2026-08-18 | Q1FY26 | NATCO PHARMA LIMITED, PHARMA LIMITED | Read the call |
| 2026-06-04 | Q4FY26 | Candice Pereira:, NATCO PHARMA LIMITED, PHARMA LIMITED, Rajesh Chebiyam: | Read the call |
| 2025-11-20 | Q2FY26 | Read the call | |
| 2025-06-04 | Q4FY24 | Read the call | |
| 2025-02-19 | Q3FY25 | PHARMA LIMITED | Read the call |
| 2024-08-21 | Q1FY25 | PRIVATE LIMITED | Read the call |
| 2024-06-04 | Q4FY24 | PRIVATE LIMITED | Read the call |
| 2024-02-21 | Q3FY24 | PRIVATE LIMITED | Read the call |
| 2023-08-14 | Q1FY24 | Kunal Randeria:, Rajesh Chebiyam: | Read the call |
| 2023-06-01 | Q4FY23 | MANAGEMENT | Read the call |
| 2023-02-13 | Q3FY23 | Read the call | |
| 2022-08-17 | Q1FY22 | Read the call | |
| 2022-06-04 | Q4FY22 | EXECUTIVE, LIMITED, RAJESH | Read the call |
Some earlier announcements under this heading are covering letters only — no transcript was attached.
What they said about it, quarter by quarter
| Topic | Q2FY26 | Q3FY23 | Q3FY24 | Q3FY25 | Q4FY22 | Q4FY23 | Q4FY24 | Q4FY26 |
|---|---|---|---|---|---|---|---|---|
| Capex | — | — | Yes, so my first question is with respect to capex. | — | And in the next 12 months, what investments are planned, either people or CAPEX or anything, any kind of? | — | I just wanted to understand with so much cash in hand, do we have any significant CAPEX plan this year? | — |
| Capital allocation | In the last call, you have mentioned that we were looking for some acquisition. | And we're also looking for an acquisition, Venkat. | We're looking for a good acquisition in the RoW business. | Regarding the use of it, we are looking at acquisition. | So recently we started a division to cover the general physician and all, but that will take sometimes the uptake to happen or to I think as I said we… | One is an acquisition what we've been talking about that. | So, even with an acquisition plan, which you have suggested in the past, are the promoters and Board not considering a buyback? | And that's, I think, a superior use of our cash rather than -- buyback can also be considered at the right time. |
| Costs | — | — | And the other one was on the raw material front that if you could just give us a number as to how much is our dependence on China for the raw material… | — | Next year, expenses will be characterized in three categories Kartik, it will be one in bio-clinical studies or clinical studies, two in what you call… | And I think we also booked -- we had to pay a raw material supplier a little bit, so -- as part of a pre-agreed agreement. | So, you are planning to launch some products and buy some raw material and then it was discarded? | So we have already seen 25% to 30% increase in the input raw materials. |
| Debt and cash | — | I mean, we have almost INR 1,030 crores of cash on the books and we have very little debt except for working capital debt, we don't have any debt at a… | And finally, with respect to the free cash flow, what was the free cash flow generation for the period -- for the 9 months or 6 months or whatever, if… | A lot of these projects that you start, you can't stop and based on your cash flow, there will be a mismatch between your cash flow and the actual exp… | 300 crores I would say and then everything we get on that top is from there and remove if you lose some extra R&D or do some extra R&D spend because o… | Secondly, I think the cash flow, we see some intangible asset purchase of INR50 crores, what would that be? | Actually, we had some tax payments and some vendor payments to make But actual cash flow is Rs. | — |
| Demand | We have shared our Para-IV pipeline, which is there in our presentation. | We have other products in pipeline and we will launch them over next period of next few years, and some of them involve patent litigation as well. | But I think we have a reasonable pipeline. | Sir, in U.S., barring Revlimid, you have a good pipeline of 24 FTF, if I have it correctly from your presentation. | One of them is Semaglutide and other one is Acalabrutinib, both have multiple pilots, so that is on those two products and we have another filing, I t… | We try to globalize and use the R&D pipeline that we have to extend a multiple number of markets so that we strengthen the businesses. | And sir, I just wanted to have a brief about how is the demand shaping up for the export customers, like all the geopolitical crisis, Red Sea crisis, … | So I mean, we have filings obviously in the pipeline. |
| Guidance | If you file in December, we are hoping that will be in the first wave, which is we are hoping the market will open around March, so, we expect around … | And anything said on this call, which reflects our outlook for the future must be reviewed in conjunction with the risks that the company faces. | So, my first question is with regards to your guidance for FY '24, where earlier you had stated -- or we were expecting profits of close to INR1,000 c… | And so for this current quarter, can we expect, I mean, it would be better than the fourth quarter of the previous year or this fourth quarter of Marc… | During this call, we may be making certain forward-looking statements or statements about future events and anything said on this call which reflects … | And what is your guidance for the next 2 to 3 years? | So, do we anticipate any significant moves to revenue from this in the upcoming years? | And anything said on this call, which reflects our outlook for the future must be reviewed in conjunction with the risks that the company faces. |
| Margin | So, we are at least close to EBITDA positive now. | Now, this development of pesticide is definitely a good idea, but that is how the company is looking for making up the losses or they are planning to … | Or if the sales increases, will the margin will also increase? | Would you be able to share what your, say, EBITDA margin was on a pre-R&D basis? | 400 crores, but the normalized sales in the rest of the business, how much would that be and related question is, we used to want a kind of quite heal… | So this quarter, we've seen a significant gross margin decline Q-o-Q as well as Y-o-Y. | So, I think we need to hit about INR160 crores to INR170 crores at least to have that EBITDA positive. | — |
| People | — | — | — | — | This is after hiring, actually our yield is even much higher is at almost 15 to 17 lakhs because we have hired to me- Natco Pharma Limited May 31, 202… | — | So, because we are not utilizing the intermediate capability, we had to make a provision for non-utilization of that. | — |
| Pricing | So, sir, by the time you are saying that you will be in the first wave in March 2026, that drug will be around nine months old in the Indian market, a… | Mr. Rajeev, we have been seeing that competitors are able to perform better in the domestic market from the growth point of view, while we are seeing … | Because from the prior commentary, we were understanding that there has been volume growth, pricing has started getting better. | See, there is some, I don't want to get into the pricing of the product. | I think in terms of Revlimid pricing, I had a conversation with Teva on this, I think Teve doesn’t want to reveal the pricing strategy, so I will not … | I was asking more from a pricing environment, do you see... | Again, we can't predict the future of what trajectory of pricing is. | — |
| Revenue growth | — | So our expectation is that, this year, overall as a company, I think, we should do about INR 2,700 crores to INR 2,800 crores in top line, and this ye… | And I think the growth of these brands are not so large that justify the valuations. | — | — | And then domestic in combination with the acquisition and growth of 10%, I think we should be able to see some positive cash flow. | And last question is about how do you see the top line for FY '25 and EBITDA margin like what we can expect? | I get that in our overall portfolio, it helps us diversify our revenue growth and everything. |